PLoS Neglected Tropical Diseases (Nov 2020)

The economic burden of dengue fever in the Kingdom of Saudi Arabia.

  • Naeema A Akbar,
  • Abdullah M Assiri,
  • Omima I Shabouni,
  • Osama M Alwafi,
  • Rajaa Al-Raddadi,
  • Mohamad H Alzahrani,
  • Esam I Azhar,
  • Ashraf Amir,
  • Abdullah M Aljiffri,
  • Abdulhakeem O Althaqafi

DOI
https://doi.org/10.1371/journal.pntd.0008847
Journal volume & issue
Vol. 14, no. 11
p. e0008847

Abstract

Read online

Rapid urbanization, global trade, and the exceptionally great numbers of worldwide visitors during Hajj and Umrah have all placed the Kingdom of Saudi Arabia at a significant risk of introducing several vector-borne tropical diseases, such as dengue fever virus (DENV) infection. In this study we estimated DENV infection cost of illness (COI) in Saudi Arabia in the period 2013-2017, by processing national data including all declared cases recorded in referral centers in the western region, being the endemic region of the country. Using a statistically validated predictive model that was built on a representative sample of 717 laboratory-confirmed cases of DENV infection, direct costs, due to care-related expenditures, were estimated by applying the predictive equation to national data. However, indirect costs, which are due to productivity loss, were estimated using the human capital model based on gross domestic product adjusted for invalidity duration. Further, under-reporting was adjusted by using an expansion factor EF = 3. We observed highest estimated costs in 2016 with over US$168.5 Million total costs, including direct (US$29.0 Million) and indirect (US$139.5 Million) costs, for a total 4415 confirmed cases. The total DENV COI for the five years was estimated as US$551.0 Million for a total 15,369 patients (59.7%) out of 25,745 declared cases, resulting in an average cost of US$11 947.6 by patient. Depending on the year, productivity years loss costs accounted for 63.3% to 83.8% of the estimated total costs. Dengue has a substantial local economic burden that costs US$110.2 Million per year, stressing the urgent need for an effective national prevention strategy to perform considerable cost-savings besides reducing morbidity.